Get the Stockscreener App
1.53
12.50%
0.17
Acumen Pharmaceuticals Inc stock is traded at $1.53, with a volume of 919.41K.
It is up +12.50% in the last 24 hours and down -8.38% over the past month.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
See More
Previous Close:
$1.36
Open:
$1.36
24h Volume:
919.41K
Relative Volume:
2.11
Market Cap:
$92.68M
Revenue:
-
Net Income/Loss:
$-64.86M
P/E Ratio:
-1.3661
EPS:
-1.12
Net Cash Flow:
$-55.66M
1W Performance:
+7.75%
1M Performance:
-8.38%
6M Performance:
+10.07%
1Y Performance:
-45.55%
1-Day Range:
$1.36
$1.60
1-Week Range:
$1.35
$1.60
52-Week Range:
$0.8551
$3.36
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Name
Acumen Pharmaceuticals Inc
Sector
Industry
Phone
617-344-4190
Address
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.53 | 86.62M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jul-26-24 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-20-23 | Resumed | BofA Securities | Buy |
| May-18-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-15-22 | Initiated | BTIG Research | Buy |
| Jun-30-22 | Initiated | H.C. Wainwright | Buy |
| Jan-21-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-26-21 | Initiated | BofA Securities | Neutral |
| Jul-26-21 | Initiated | Credit Suisse | Outperform |
| Jul-26-21 | Initiated | Stifel | Buy |
| Jul-26-21 | Initiated | UBS | Buy |
View All
Acumen Pharmaceuticals Inc Stock (ABOS) Latest News
How high can Acumen Pharmaceuticals Inc. stock goWeekly Volume Report & Risk Managed Investment Strategies - Newser
Acumen Pharmaceuticals Inc. stock momentum explainedPortfolio Performance Summary & Smart Money Movement Tracker - Newser
What Technical Tools Say About Acumen Pharmaceuticals Inc. RecoveryTrade Analysis Summary & Weekly Setup with High ROI Potential - newsyoung.net
Using data tools to time your Acumen Pharmaceuticals Inc. exitQuarterly Earnings Summary & Short-Term High Return Strategies - Newser
Published on: 2025-08-20 04:13:48 - Newser
Is this a good reentry point in Acumen Pharmaceuticals Inc.Portfolio Profit Report & Low Risk Profit Maximizing Plans - Newser
Visual trend scoring systems applied to Acumen Pharmaceuticals Inc.Recession Risk & High Return Stock Watch Alerts - Newser
Tick level data insight on Acumen Pharmaceuticals Inc. volatilityJuly 2025 Trade Ideas & Free Real-Time Market Sentiment Alerts - Newser
What institutional flow reveals about Acumen Pharmaceuticals Inc.2025 Momentum Check & Risk Adjusted Swing Trade Ideas - Newser
How moving averages guide Acumen Pharmaceuticals Inc. tradingDividend Hike & Stepwise Trade Execution Plans - Newser
Volume spikes in Acumen Pharmaceuticals Inc. stock – what they meanQuarterly Growth Report & Stock Timing and Entry Methods - Newser
Is This a Bottoming Phase for Acumen Pharmaceuticals Inc.July 2025 Review & Capital Efficient Trading Techniques - newsyoung.net
Technical analysis overview for Acumen Pharmaceuticals Inc. stockJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - Newser
Advanced analytics toolkit walkthrough for Acumen Pharmaceuticals Inc.July 2025 Analyst Calls & Precise Buy Zone Tips - Newser
Developing predictive dashboards with Acumen Pharmaceuticals Inc. dataTrade Analysis Report & Expert-Curated Trade Recommendations - Newser
What’s the recovery path for long term holders of Acumen Pharmaceuticals Inc.July 2025 Volume & Smart Investment Allocation Insights - Newser
Analyzing drawdowns of Acumen Pharmaceuticals Inc. with statistical toolsJuly 2025 PreEarnings & Verified Technical Trade Signals - Newser
Should you wait for a breakout in Acumen Pharmaceuticals Inc.Trade Risk Assessment & Long-Term Safe Investment Ideas - Newser
Published on: 2025-08-19 04:29:22 - Newser
What’s next for Acumen Pharmaceuticals Inc. stock pricePortfolio Update Report & Weekly Hot Stock Watchlists - Newser
Will Acumen Pharmaceuticals Inc. price bounce be sustainableQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - Newser
Will Acumen Pharmaceuticals Inc. benefit from macro trendsWeekly Stock Report & High Return Trade Guides - Newser
Is Acumen Pharmaceuticals Inc. stock entering bullish territoryProduct Launch & Fast Exit/Entry Strategy Plans - Newser
Can machine learning forecast Acumen Pharmaceuticals Inc. recoveryWeekly Stock Recap & Real-Time Market Sentiment Alerts - Newser
Evaluating Acumen Pharmaceuticals Inc. with trendline analysisPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Can Acumen Pharmaceuticals Inc. sustain its profitabilityWeekly Market Summary & Long Hold Capital Preservation Plans - thegnnews.com
How to build a dashboard for Acumen Pharmaceuticals Inc. stockJuly 2025 Institutional & Low Risk Entry Point Tips - Newser
Analysts Offer Predictions for ABOS FY2025 Earnings - Defense World
Key metrics from Acumen Pharmaceuticals Inc.’s quarterly dataWeekly Volume Report & High Conviction Buy Zone Picks - Newser
How Acumen Pharmaceuticals Inc. stock performs during market volatility2025 Risk Factors & High Win Rate Trade Alerts - Newser
BTIG Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen expects ALTITUDE-AD Phase II top line results in late 2026 as JCR partnership advances next-generation Alzheimer’s candidates - MSN
Acumen Pharmaceuticals Inc Stock (ABOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acumen Pharmaceuticals Inc Stock (ABOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):